News

Synexus hopes to have the new sites completed by March 2009. Synexus, which acquired the clinical trial business CRC in 2006, said that it has found South Africa

Celera will use Nanogen’s minor groove binder (MGB) technology to develop in vitro diagnostic products for cardiovascular and oncological applications. This is an expansion of the original license

Dr Rothenberg comes to Pfizer from Vanderbilt where he was professor of medicine at the Vanderbilt University Medical Center and Ingram professor of cancer research at the Vanderbilt-Ingram

The challenge to validity was made by way of an application by Generics UK for a declaration that the supplementary protection certificate (SPC) and the patent on which

About 40% of the total reductions will occur in the US. To streamline management layers across the company, Merck will reduce its total number of senior and mid-level

The company has reported net income of $1.14 billion for the third quarter of 2008, compared to $1.14 billion for the third quarter of 2007. Diluted earnings per

The new study, the first to be sponsored by the drug’s developers, will reconfirm dose ranging and will use the gold standard of the randomized, double-blind, placebo controlled

The expanded and updated results continue to indicate that picoplatin, given once every four weeks in combination with 5-fluorouracil and leucovorin (FOLPI), is associated with less frequent and

In preclinical studies, IPI-493 potently inhibits heat shock protein 90 (Hsp90) and has strong pharmaceutical properties in vitro and in vivo, including selectivity for cancer cells over normal